RxDoctor Payments DataLook up a doctor →

Matthew Allaway, DO

Urology · Cumberland, MDNPI 1386750057

Payments from drug & device makers

$20,627,081in general payments, 2019–2025

Across 168 payments — averaging $122,780 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$20.6M
  • AbbVie$639
  • Pfizer$477
  • Astellas Pharma US Inc$413
  • Sumitomo Pharma America, Inc.$364
  • Laborie Medical Technologies Corp.$223
  • plus $996 from 19 others

What the payments were for

  • Speaking & faculty fees$29,6500%
  • Travel & lodging$1,4500%
  • Food & beverage$3,3770%
  • Education$1860%
  • Other$20,592,418100%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$20,627,081 in reported general payments places this provider in the 95th percentile of 274 urology providers in Maryland.

See all urology providers in Maryland

Medicare billing

Part B allowed, 2024
$757,532
Medicare patients
1,593
Services billed
15,961

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide29$409,052
MyrbetriqMirabegron188$144,217
Abiraterone Acetate15$109,432
GemtesaVibegron89$71,579
ElmironPentosan Polysulfate Sodium14$12,220
Tamsulosin Hcl680$11,484
Testosterone Cypionate156$8,538
NitrofurantoinNitrofurantoin Macrocrystal223$6,396
Alfuzosin Hcl ErAlfuzosin Hcl205$5,908
Oxybutynin Chloride ErOxybutynin Chloride212$5,357
Testosterone47$5,216
Potassium Citrate ErPotassium Citrate94$4,879
Finasteride242$4,238
Trospium Chloride ErTrospium Chloride11$2,735
Desmopressin Acetate50$2,212

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$413$553,269217 claims
Sumitomo Pharma America, Inc.Gemtesa$364$71,57989 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 274 urology providers in Maryland.

Other urology in Cumberland

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →